CLINICAL_TRIALS
trial_result
· 2016-09-21
Clinical Trial Update: Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma [Phase 1]
Summary
Phase 1 study evaluating the combination of bevacizumab with buparlisib (BKM-120) in patients with metastatic renal cell carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Toni Choueiri, MD | Conditions: Renal Cell Carcinoma | Phase 1 | Status: COMPLETED